Today Exact Sciences released earnings for the third quarter of 2017. Results exceeded our expectations with revenue of $72.6 million, up 26% from the second quarter, and 161,000 completed Cologuard tests, up 19% from the second quarter.
Exact Sciences recently announced 2017 second quarter earnings results, which exceeded our expectations. Revenue reached $57.6 million, up 19% sequentially, and completed Cologuard test volume totaled 135,000, up 35% sequentially.
Exact Sciences recently announced our first quarter 2017 financial results, highlighting the accelerating growth trajectory for Cologuard. Beyond the headline-making news, we continue to see a large market opportunity for Cologuard. While changing the standard of care will take time and investment in our infrastructure, we have never been more confident in the long-term growth of Cologuard and Exact Sciences.